넥스트바이오메디컬

389650KOSDAQ

51.3 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 22.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NextBioMedical is a biopharma company specializing in drug delivery systems, biocompatible medical devices, and oncology treatments. It focuses on developing pharmaceutical-medical device convergence products, particularly drug-eluting beads for liver cancer therapy and interventional radiology technologies.

Number of Employees

81people

Average Salary

45.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

5.34Industry Average 1.200.0Point

4.5x industry avg (risky)

ROE

-0.67Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.47Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲72.7% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲79.9% (1-year basis)

ROE Trend

0.0 / 4

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
넥스트바이오메디컬, 넥스피어에프 美 진입 속도전...매출 퀀텀점프 .....
넥스트바이오메디컬의 미국 시장 진출 가속화로 매출 퀀텀점프 기대.
Positive
넥스파우더로 세계 뚫은 넥스트바이오메디컬, 2년 연속 ‘코스닥 라이.....
넥스트바이오메디컬의 넥스파우더가 국제 규제 기관 승인을 획득하며 글로벌 시장 진출에 성공, 긍정적인 주가 전망.
Positive
넥스트바이오메디컬, 코스닥 라이징스타 2년 연속 선정
넥스트바이오메디컬이 코스닥 라이징스타로 선정되어 기술 및 성장 잠재력이 인정받았다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 31,050Won52-week high 98,00052-week low 31,050

1-month return0.0Point

1m -22.47% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업설명회(IR)개최2026-09-01
Neutral[기재정정]분기보고서 (2026.03)2026-08-19
Neutral반기보고서 (2026.06)2026-08-10